Human papillomavirus genotypes associated with cervical precancerous lesions and cancer in the highest area of cervical cancer mortality, Longnan, China

Jin Zhao, Zhong Guo, Qiang Wang, Tianbin Si, Shuyan Pei, Chenjing Wang, Hongmei Qu, Jianbin Zhong, Ying Ma, Cong Nie and Dan Zhang

Abstract

Background: The mortality of cervical cancer in Longnan is as high as 39/10 million, ranking first in China.

Methods: Between 2012 to 2016, 329 samples with cervicitis, cervical intraepithelial neoplasia grade 1 to 3 (CINI to III), and invasive squamous cell carcinoma (SCC) were collected. HPV genotypes were examined with a validated kit for 23 different HPV subtypes.

Results: Compared to cervicitis, the HPV positivity is significantly higher in CINI, CIN II/III, and SCC (38.60%, 74.60%, 87.50% and 89.05%, P<0.001) and the positivity is also higher in SCC compared to CINI (P<0.01).

The most frequently detected genotypes were HPV16 in cervicitis, HPV16, 58 and 52 in CINI and CIN II/III, and HPV16, 58 and 18 in SCC groups. HPV16 positivity in cervicitis, CINI, CIN II/III, and SCC patients were 45.46%, 46.81%, 60.32% and 78.69%, respectively. Compared to cervicitis and CINI, the odds ratios (OR) for SCC in HPV16 positive patients were 2.96 (95% confidence interval [CI]: 1.09–8.00, P<0.05) and 4.20 (95% confidence interval [CI]: 2.05–8.61, P<0.001), respectively. In addition, the multiple infections in cervicitis, CINI, CINII/III and SCC group are 9.09%, 27.66%, 26.98% and 25.41% and HPV16 + 58 was the most common combinations.

Conclusion: These findings highlight the key role of HPV16, 58, 52 and 18 in the development of CIN and SCC in Longnan women and a fully aware of regional differences in HPV genotype distribution are tasks for cervical cancer control and prevention.

Keywords: Human papillomaviruses, Cervicitis, Cervical intraepithelial neoplasia grade I to III, Invasive squamous cell carcinoma
that persistent HPV infection is considered to play a key role in the development of CC [9]. Cervical intraepithelial neoplasia (CIN) reflects a continuous and progressive CC process, and high grade squamous intraepithelial lesions (HSIL) with HPV infection, can develop and progress to CC over a period of 8 to 12 years [10].

The prevalence of HPV infection and the reported type-specific distribution varies greatly by geographic region and ethnicity. For example, HPV16 is slightly more prevalent in Europe and North America, HPV 31 is more prevalent in South/Central America, HPV 33 and 45 are more prevalent in Africa, and HPV 52 and 58 are more prevalent in Asia [9, 11–17]. Furthermore, the data from mainland China indicated that HPV16, 18, 33, and 58 were the most common types in women with CC in Henan, central China [18], whereas HPV16, 58, 18 and 33 were the most prevalent types in CIN2+ (high-grade cervical lesions, including CINII/III, and CC) in women in Liaoning, northeast China [19], and HPV16 and 58 were the most common types in CC and high-grade precancerous lesions in Chengdu, southwestern China [20].

Longnan of Gansu Province, located in the remote areas of Northwest of China, is the high incidence areas of cervical cancer and cervical cancer mortality as high as 39/10 million, ranking first in China [21]. This study aims to investigate the prevalence and distribution of HPV oncogenic genotypes in patients with cervicitis, CINI, CINII/III, or invasive squamous cell carcinoma (SCC) in Longnan. The results will help to establish more cost-effective follow up and guiding significance for cervical cancer prevention.

Methods

Study subjects

A total of 329 Longnan patients aged 17~79 years samples were initially included in the present study between January 1, 2012, and January 30, 2016: 57 in the cervicitis group, 63 in the CINI group, 72 in the CINII/III group, and 137 in the SCC group. All the samples were obtained from patients who underwent biopsies with colposcopy or advanced operations. In all of samples, 305 were obtained at the No.1 Hospital of Longnan City as well as 24 samples from Gansu Provincial Cancer Hospital. All patients gave written informed consent for their participation. This study has been approved by the Ethics Committees of Northwest University for Nationalities prior to its start. All the samples were formalin-fixed and paraffin-embedded. All specimens were evaluated by at least 2 experienced pathologists in their respective hospital’s pathology department. Cervicitis, CINI, CINII/III and squamous cervical cancer (SCC) were diagnosed according to the standard criteria [22].

HPV genotype screening using the human papillomavirus genotyping kit

The Human Papillomavirus Genotyping kit for 23 Types was produced by Yaneng Bioscience co., LTD (Shen Zhen, China), and the kit was applied for with permit number 3400994 in 2008 by the Fresh Armed State Drug Administration, China. The kit was used to perform polymerase chain reaction (PCR) to amplify the L1 gene in conjunction with reverse dot blot (RDB) analysis to identify the HPV subtypes. This method offers a simple testing strategy involving a membrane chip that can detect infections from multiple HPV subtypes, including 18 high-risk types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 83 and MM4) and 5 low-risk types (HPV 6, 11, 42, 43 and 44). This method had a sensitivity of 103 copies/ml and a specificity of 99%; β-globin was used as an internal positive control [23].

DNA extraction and polymerase chain reaction (PCR) conditions

DNA was extracted from 4–5 serial sections (4 μm thick) by hot dehiscing using the Human Papillomavirus Genotyping kit for 23 Types, according to the manufacturer’s instructions. The tissues prepared for extraction included representative tumor tissues and the adjacent normal tissue. The quality of the extracted DNA was verified using a spectrophotometer (260/280 nm ultraviolet light). The extracted DNA was concentrated by high-speed centrifugation at 4 °C. For each PCR reaction, 5 μL extracted concentrated DNA was used in a final reaction volume of 25 μL. The PCR amplification conditions were as follows: preheating at 95 °C for 10 min, followed by 40 cycles of denaturation at 94 °C for 30 s, annealing at 42 °C for 90 s, and extension at 72 °C for 30 s, with a final extension at 72 °C for 5 min. The amplification were then denatured and subjected to hybridization.

To test the quality of the DNA, the kit was also used to amplify the housekeeping gene β-globin within the same reactions as an internal positive control. We also used a verified HPV multiple infection cervical intraepithelial neoplasia sample as a positive control and distilled water as a negative control; all control samples were subject to the same treatments and processed at the same time as the experimental samples. To ensure the samples were not contaminated within the lab, every test was carried out with fresh wash buffer and all samples were independently tested in two isolated labs by blind assignment.

HPV detection and typing

We use the reverse dot blot (RDB) method for HPV detection and typing. The 25 μL reaction volumes containing the amplified fragments were hybridized to
the dot blot membrane in 6 mL hybridization solution (2 × SSC, 0.1% SDS) at 51 °C for 2 h. After a stringent wash, the hybridized membrane was probed by adding a streptavidin-horseradish peroxidase conjugate (which binds to the biotinylated PCR products) and a substrate (3,3′,5,5′-Tetramethylbenzidine) to generate a blue precipitate at the site of the probe dot. The results were inspected by macroscopic observation, and the results were deemed reliable when the PC (positive control) dot appeared as a clear round blue dot. A clear round blue dot was scored as positive for the corresponding HPV subtype, a dilute blue dot was scored as weakly positive, and the absence of a dot was scored as negative.

Statistical analysis
Statistical analysis was performed using SPSS version 19.0 (SPSS, Chicago, IL). Differences between groups were examined using the $\chi^2$, or Fisher’s exact probability test according to the characteristics of the data distribution. The odds ratio (OR) and relative 95% confidence interval (CI) were calculated. The significance level $\alpha$ was set at 0.05.

Results
Genotypes detected in Cervicitis, CINI, CINII/III and SCC
We identified 329 eligible patients with a mean age of 43.5 years (range, 17 ~ 79) from the medical records. Of these patients, 57 were confirmed as cervicitis, 63 were CINI, 72 were CINII/III, and 137 cases were SCC. The HPV positive rates in the cervicitis, CINI, CINII/III and SCC were 38.60% (22/57), 74.60% (47/63), 87.50% (63/72) and 89.05% (122/137), respectively; the HPV positive rate was significantly higher in CINI, CINII/III and SCC than that in cervicitis ($P < 0.001$). and the positivity is also higher in SCC compared to CINI ($P < 0.01$, Fig. 1).

The distribution of HPV genotypes according to cervical lesions is shown in Fig 2. HPV16 was the most common genotype in cervicitis, accounting for 45.46% (10/22). In the CINI group, HPV16 was the most common genotype, accounting for 46.81% (22/47), followed by HPV58 (21.28%, 10/47), HPV52 (17.02%, 8/47), HPV33 (12.77%, 6/47), HPV51 (6.38%, 3/47) and 59 (6.38%, 3/47). For the CIN III group, HPV16 was also the most common genotype, accounting for 60.32% (38/63), followed by HPV58 (25.40%, 16/63), HPV52 (12.70%, 8/63), HPV31 (6.35%, 4/63) and 33 (6.35%, 4/63). The 5 most common genotypes in patients with SCC were HPV16 (78.69%, 96/122), HPV58 (20.49%, 25/122), HPV18 (6.56%, 8/122), HPV59 (4.92%, 6/122) and 52 (4.10%, 5/122), in descending order. None genotype of the differences between groups were significant except HPV16 infection in SCC compared to cervicitis, CINI and CINII/III ($P < 0.001$, $P < 0.01$. Fig. 2).

OR for HPV16 infection
Because HPV16 was significantly higher in invasive SCC, logistic regression analysis was used to calculate the odds ratios (OR) and 95% confident intervals (95%CI) of such infections. Compared to cervicitis and CINI, the odds ratios (OR) for SCC in HPV16 positive patients were 2.96 (95% confidence interval [CI]: 1.09–8.00, $P < 0.05$) and 4.20 (95% confidence interval [CI]: 2.05–8.61, $P < 0.001$, respectively (Table 1).

HPV genotypes of multiple infections in Cervicitis, CINI, CINII/III and SCC
Some women were infected with 2 or 3 types of HPV simultaneously (Table 2). Compared to cervicitis (9.09%, 2/22), more patients with CINI, CINII/III and SCC had multiple HPV infections, however, as the cervical lesion grade increased, the prevalence of multiple HPV infections gradually deceased (27.66%, 13/47; 26.98%, 17/63 and 25.41%, 31/122, respectively). Double infections accounted for the majority of multiple infections, 4.55%(1/22), 21.28%(10/47), 20.64%(13/63) and 21.31%(26/122) for cervicitis, CINI, CINII/III and SCC respectively. Of those, HPV16 + 58 was the most common combinations, and HPV52 + 33 in CINI subgroup, HPV16 + 52 in CINII/III subgroup were also common genotypes combination. In the cervicitis, CINI, CINII/III and SCC subgroups, 4.5%(1/22), 6.38%(3/47), 6.35%(4/63), 4.10%(5/122) of patients had triple HPV infections. The combinations and prevalence of the HPV genotypes in multiple infections for each cervical lesion group and subgroup are specified in Table 3.
Discussion

Our data showed that 38.60% of patients with cervicitis, 74.60% with CINI, 87.50% with CINII∕III, and 89.05% with SCC were positive for HPV DNA. HPV infection rates were significantly higher in CINI, CINII∕III, and invasive SCC than in cervicitis patients, but they never reached 100%. In addition, in our population, HPV 16 was the dominant genotype and HPV 33, 53, 58 and 59 were the second dominant genotypes for cervicitis. HPV genotypes 16, 58, and 52 were the dominant high-risk HPV in patients with CINI and CINII∕III, however for invasive SCC, the dominant high-risk HPV were 16, 58 and 18. Besides of the genotypes suggested above, HPV 6, 11, 31, 33, 51, 56 and 59 also were detected. In some reports in which HPV16, 18, and 45, HPV16, 18 and 33 or 16, 18 and 58 were most commonly detected in cervicitis [11, 24–26], CINI, CINII∕III and SCC patients. Despite the small sample size of our subgroup, the dominant genotypes remained stable across the cervicitis, CINI, CINII∕III and SCC groups, which supported the credibility of our data. In addition, HPV16 was significantly associated with SCC, the ORs were 2.96 (CI: 1.09–8.00) and 4.20 (CI: 2.05–8.61), respectively, when compared to cervicitis and CINI. The absence of a similar significant association between other genotypes may have been due to the small size of study groups.

In our group of CINI, CINII∕III and SCC patients, the positivity for HPV DNA are consistent with those in most other studies [11, 24–30]. For example, the reports from Shanghai of 239 patients with CINI and USA of 411 patients with CINII∕III, in which the rates of HPV DNA positivity were 74.9% and 82.0–92.0%. For the regions of worldwide, the rate of HPV DNA positivity in SCC was 87.0–90.9%. In addition, the positivity of HPV16 infection in CINI, CINII∕III and SCC patients is 46.81%, 60.32% and 78.69% respectively, which is also consistent with the most reports [11, 24, 31, 32]. These evidences further suggested that the performance of HPV detection kit is credible and our data likely reflect the real association pattern between HPV infection and cervical cancer or precancerous lesions in local area.

The distribution of dominant HPV genotypes showed obvious regional differences [33]. HPV18 is reported to be one of the two most carcinogenic HPV genotypes (HPV16 and 18), accounting for 10~15% of cervical cancers [11, 24, 32]. In our population, the prevalence of HPV18 in patients with cervicitis, CIN I, CIN II∕III and invasive SCC were 0%, 2.13%, 1.59% and 6.56%, respectively. The overall prevalence rate of HPV18 is very lower, but consistent with a recent Korea report, where only 6 (2.5%) out of the 243 high-risk HPV positive subjects showed HPV18 infection [34]. HPV52 is also considered as a high-risk genotype and is especially frequent in Northern America, Africa, and Asia [35, 36]. In our population, the prevalence of HPV52 in patients with cervicitis, CIN I, CIN II∕III and invasive SCC were 4.55%, 17.02%, 12.70% and 4.10%, respectively and was largely higher than in other reports, in which HPV52 prevalent rates ranged up to 2.4% in women with normal cytological findings, 5.1% in women with CIN II∕III and were 2.5% in women with SCC [36]. In present study, HPV 58 is a dominant high-risk genotype and the prevalence of HPV58 in patients with cervicitis, CIN I, CIN II∕III and invasive SCC was 9.09%, 21.28%, 25.40 and 20.49%, respectively. Although the overall prevalence...
rate of HPV58 in our research is very higher than the reports of Japanese and world, in which HPV58 prevalence rates are 7.0% in patients with CIN II/III and 3.3% ~ 13.3% in patients with SCC [10, 37], our result is consistent with some recent Chinese reports [33, 38], where 16.4%, 20.1%, 23.5% and 31.4% patients with cervicitis, CIN I, CIN II/III and invasive SCC and 29.1% and 24.3% patients with CIN II/III and invasive SCC showed HPV58 infection.

Our data suggested that more patients with CINI, CIN II/III and SCC had multiple HPV infections compared to cervicitis, however, the rates of multiple HPV infections in CIN I, CIN II/III and SCC patients showed a slightly decreasing trend with severity of lesions. Although this

Table 2 Simple and multiple of HPV infections in the study groups

| Genotype   | Simple infections | Multiple infections |
|------------|-------------------|---------------------|
|            |                   | Double              | Triple | Total        |
| cervicitis | 90.91% (20/22)    | 4.55% (1/22)        | 4.5% (1/22) | 9.09% (2/22) |
| CIN I      | 72.34% (34/47)    | 21.28% (10/47)      | 6.38% (3/47) | 27.66% (13/47) |
| CIN II/III | 73.02% (46/63)    | 20.64% (13/63)      | 6.35% (4/63) | 26.98% (17/63) |
| SCC        | 74.59% (91/122)   | 21.31% (26/122)     | 4.10% (5/122) | 25.41% (31/122) |

Abbreviations: HPV human papillomavirus, CIN cervical intraepithelial neoplasia, SCC squamous cell carcinoma

Table 3 Combinations of HPV types in multiple infection in the study groups

| Genotype       | Cervicitis | CIN I   | CIN II/III | SCC          |
|----------------|------------|---------|------------|--------------|
| Combinations   |            |         |            |              |
| HPV16+18       |            |         |            | 1.64% (2/122) |
| HPV16+33       |            |         | 4.76% (3/63) | 1.64% (2/122) |
| HPV16+52       |            |         | 4.76% (3/63) |              |
| HPV16+58       |            |         | 4.26% (2/47) | 6.35% (4/63) | 9.84% (12/122) |
| HPV16+other types |         |         | 6.38% (3/47) | 1.59% (1/63) | 5.74% (7/122) |
| HPV51+11       |            |         | 2.13% (1/47) |              |
| HPV52+31       |            |         | 2.13% (1/47) |              |
| HPV52+56       |            |         |              | 0.82% (1/122) |
| HPV52+33       |            |         | 4.26% (2/47) |              |
| HPV58+53       |            |         | 4.5% (1/22)  |              |
| HPV58+56       |            |         | 1.59% (1/63) |              |
| HPV58+59       |            |         | 0.82% (1/122) |              |
| HPV58+other types |         |         | 1.59% (1/63) | 0.82% (1/122) |
| Combinations   |            |         |            |              |
| HPV16+18+33    |            |         | 0.82% (1/122) |              |
| HPV16+18+59    |            |         | 0.82% (1/122) |              |
| HPV16+31+33    |            |         | 1.59% (1/63) |              |
| HPV16+56+81    |            |         | 0.82% (1/122) |              |
| HPV16+58+31    |            |         | 0.82% (1/122) |              |
| HPV16+58+33    |            |         | 2.13% (1/47) |              |
| HPV16+58+43    |            |         | 1.59% (1/63) |              |
| HPV16+59+43    |            |         | 0.82% (1/122) |              |
| HPV18+33+35    |            |         | 2.13% (1/47) |              |
| HPV18+58+31    |            |         | 1.59% (1/63) |              |
| HPV45+53+59    |            |         | 4.5% (1/22)  |              |
| HPV58+31+42    |            |         | 1.59% (1/63) |              |

Abbreviations: HPV human papillomavirus, CIN cervical intraepithelial neoplasia, SCC squamous cell carcinoma
finding is partially consistent with the results of previous studies, in which Francois et al. and Meizhu Xiao et al. found that the rates of multiple hr-HPV infections in CINII, CINIII, and CC patients declined gradually [38, 39], the rates of multiple HPV infections of our survey was significantly lower than in these reports. This difference may occur because the prevalence of HPV-positive status also vary among geographic locations and populations. Moreover, the small size of group in our study may be one of the reason of lower positivity of multiple HPV infections. However, in a worldwide pooled analysis of 167 adenocarcinoma of the cervix patients, the multiple-infection rate was 8.9%, obviously lower than the simple infection prevalence of 91.1% [18]. Thus, our data which reflected Multiple HPV infections might be indeed be associated with the development of cervical lesions, or women with multiple HPV infections might be more susceptible to cervicogenous, or multiple HPVs infections might produce conditions that confer immunological protection against persistent infection [40].

Our data indicated that the combination of HPV16 + 58 plays a dominant role in all cervical lesion groups, contrary to findings in the Jewish Israeli population and in Austrians, but in agreement with findings in women in Beijing, China [41–43]. Thus, the results of this study strongly support the key role of HPV16 and 58 in the development of CC and CIN in women in LongNan, China.

Conclusions
Overall, as demonstrated in our study population, genotypes 16, 58, 52 and 18 are among the predominant HPV and HPV infection increased with cervical lesion, regional differences in HPV genotype distribution and the real carcinogenic HPV revealing need to be mindful in the HPV control and prevention.

Funding
This study was supported by the National Natural Science Foundation of China (31060127, 81260442, 81560508 and 31560254) and Program for Leading Talent of SEAC (2016).

Authors’ contribution
JZ and ZG conceived and designed the study. CN and DZ collected the respective hospital pathology department. SYP and CJW performed all the molecular biology assays for HPV genotyping. HMQ, JBZ and YM analyzed the data and drafted the manuscript. All authors read and approved the final manuscript.

Competing interest
The authors declare that they have no competing interests.

Ethics approval and consent to participate
Written informed consent was obtained from each patient; approval was obtained from the Ethics Committees of Northwest University for Nationalities, China (#2012–01–01).

Author details
1Medical College of Northwest University for Nationalities, Lanzhou 730030, People’s Republic of China. 2No.1 Hospital of Longnan City, Longnan 746000, People’s Republic of China. 3Gansu Provincial Cancer Hospital, Lanzhou 730050, People’s Republic of China.

Received: 14 November 2016 Accepted: 4 January 2017 Published online: 25 January 2017

References
1. Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Antiviral Infect Ther. 2010;8(5):1139–62.
2. Nobre RJ, Herdez-Hemández E, Fei JW, Langbein L, Kaden S, Gröne HJ, de Villiers EM. E7 oncoprotein of novel human papillomavirus type 108 lacking the E6 gene induces dysplasia in organotypic keratinocyte cultures. J Virol. 2009;83(7):2907–16.
3. Pillai MR, Lakshmi S, Sreekala S, Devi TG, Juyal D, Rajakalmath TN, Devi CG, Nair MK, Nair MB. High-risk human papillomavirus infection and E6 protein expression in lesions of the uterine cervix. Pathobiology. 1998;66(2):240–6.
4. Tomesello ML, Duraturo ML, Botti G, Greggi S, Piccillo R, De Palo G, Montella M, Buonaguro L, Buonaguro FM. Italian HPV working group: prevalence of α-papillomavirus genotypes in cervical intraepithelial neoplasia and cervical cancer in the Italian population. J Med Virol. 2006;78(12):1663–72.
5. Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol. 2014;234(4):431–51.
6. Hale G, Alemay L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klautzemeier JE, Guimerà N, Grabe N, Lahrman B, Gissinger L, Quint W, Bosch FX, de Sanjose S, Pawlita M. Retrospective international survey and HPV time trends study group: retrospective international survey and HPV time trends study group. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol. 2014;234(4):441–51.
7. Torres LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
8. Kim K, Zang R, Chei SC, Ryu SY, Kim JW. Current status of gynecological cancer in China. J Gynecol Oncol. 2009;20(2):172–6.
9. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBiSC) Study Group. J Natl Cancer Inst. 1995;87(11):796–802.
10. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruini L, Tortolero-Luna G, Kjaer SK, Muñoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2000;20(2):161–6.
11. de Sanjose S, Wilm GVQ, Laia A, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56.
12. Wright Jr TC, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study design, methods, and baseline results. Am J Obstet Gynecol. 2012;206(4):e1–16.
13. Diaz M, Kim JJ, Albero G, de Sanjose S, Clifford G, Bosch FX, Goldie SJ. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer. 2008;99(2):230–8.
14. Kjaer SK, Beugelmans G, Munk C, Junge J, Watson M, Itthier T. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer. 2008;123(8):1864–70.
15. Castellsagué X, Diaz M, de Sanjose S, Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98(3):303–15.
16. Schwartz SM, Daling JR, Shafer KA, Madeleine MM, McNitt B, Galloway DA, Porter PL, McDougal JK. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol. 2001;19(7):1906–15.
17. Bao YP, Li N, Smith JS, Qiao YL. ACCPAB members. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer. 2008;18(1):71–9.
18. Shen Y, Gong JM, Li YQ, Gong YM, Lei DM, Cheng GM, Li XF. Epidemiology and genotype distribution of human papillomavirus (HPV) in women of Henan Province, China. Clinica Chimica Acta. 2013;415:297–301.
19. Liu X, Zhang S, Ruan Q, Ji Y, Ma L, Zhang Y. Prevalence and type distribution of human papillomavirus in women with cervical lesions in Liaoning Province, China. Int J Gynecol Cancer. 2010;20(1):147–53.
20. Jinke L, Dan Z, Yi Z, et al. Prevalence and genotype distribution of human papillomavirus in women with cervical cancer or high grade precancerous lesions in Chengdu, western China. Int J Gynecol Obstet. 2011;112(2):131–4.

21. Yang L, Huangguo X-m, Zhang S-w, et al. Changes of mortality rate for cervical cancer during 1970’s and 1990’s periods in china. Acta Academica Medicinae Sinicae. 2003;25(4):386–90.

22. Kurman RJ, Ellenson LH, Ronnett BM. Blaustein's pathology of the female genital tract. 5th ed. New York: Springer; 2002.

23. Zhi YF, Cha XX, Li XF, Qiu C, Rong SH. Prevalence and genotype distribution of human papillomavirus in women in the Henan Province. Genet Mol Res. 2015;14(2):5452–61.

24. Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International agency for research on cancer multicenter cervical cancer study group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.

25. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype diversity in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1157–64.

26. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009;101(7):475–87.

27. Liang H, Griffith CC, Ma L, Ling B, Feng D, Li Z, Zhao C. The sensitivity of Pap cytology and HPV testing to detect incident cervical cancer: Prior testing results in 178 patients with invasive cervical cancer at a large general hospital in China. J Amer Soc Cyto. 2015;4(6):533–4.

28. Zheng B, Li Z, Griffith CC, Yan S, Chen C, Ding X, Liang X, Yang H, Zhao C. Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China’s largest CAP-certified laboratory. Cancer Cytopathol. 2015;123(7):428–34.

29. Bhatia N, Lal N, Bao YP, Ng T, Qiao YL. A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination. Vaccine. 2008;26(23):3881–7.

30. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–35.

31. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Nauleur P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T. Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.

32. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Petto J, Meijer C, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;188(1):12–9.

33. Xu Y, Ma C, Zou J, Zhu Y, Yang R, Xu Y, Zhang Y. Prevalence characteristics of high-risk human papillomaviruses in women living in Shanghai with cervical precancerous lesions and cancer. Oncotarget. 2016;7(17):24656–63.

34. Choi JW, Kim Y, Lee JH, Kim YS. The clinical performance of primary HPV screening, primary HPV screening plus cytology cotesting, and cytology alone at a tertiary care hospital. Cancer Cyto. 2016;124(2):144–52.

35. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–65.

36. Bruni L, Diaz M, Castellsagué X, Ferrez E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99.

37. Watanuki H, Michimata R, Yasuda M, Ishizu A, Tamaru U, Xiong Y, Hassan MK, Sakuragi N. High prevalence of multiple human papillomavirus infection in Japanese patients with invasive uterine cervical cancer. Pathobiology. 2011;78(4):220–6.

38. Xiao M, Xu Q, Li H, Gao H, Bie Y, Zhang Z. Prevalence of human papillomavirus genotypes among women with high-grade cervical lesions in Beijing. China Med (Baltimore). 2016;95(3), e2555.

39. Francois C, Samuel R, Aghionnotram VR, et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol. 2011;83(6):1034–41.

40. Sang Ah L, Daehoe K, Sang SS, et al. Multiple HPV infection in cervical cancer screened by HPV DNA Chip. Cancer Lett. 2003;198(2):187–92.

41. Laskov I, Grisaru D, Efrat G, et al. Are the human papillomavirus genotypes different in cervical cancer and intraepithelial neoplasia in Jewish Israeli women, a low-risk population? Int J Gynecol Cancer. 2013;23(4):730–4.

42. Lucia R, Olaf R, Reinhard H, et al. Human papillomavirus in high-grade cervical lesions Austrian data of a European multicentre study. Wien Klin Wochenschr. 2013;125(19–20):591–9.